These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 29551750)
21. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice. Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847 [TBL] [Abstract][Full Text] [Related]
22. In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Groppe JC; Wu J; Shore EM; Kaplan FS Cells Tissues Organs; 2011; 194(2-4):291-5. PubMed ID: 21525719 [TBL] [Abstract][Full Text] [Related]
23. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva. Le VQ; Wharton KA Dev Dyn; 2012 Jan; 241(1):200-14. PubMed ID: 22174087 [TBL] [Abstract][Full Text] [Related]
25. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva. Shore EM; Kaplan FS Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697 [TBL] [Abstract][Full Text] [Related]
26. Hints on transcriptional control of essential players in heterotopic ossification of Fibrodysplasia Ossificans Progressiva. Ravazzolo R; Cappato S; Bocciardi R Bone; 2018 Apr; 109():187-191. PubMed ID: 29100956 [TBL] [Abstract][Full Text] [Related]
27. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP). Towler OW; Shore EM Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058 [TBL] [Abstract][Full Text] [Related]
28. ALK2 Receptor Kinase Association with FKBP12.6 Is Structurally Conserved with the ALK2-FKBP12 Complex. Williams E; Riesebos E; Kerr G; Bullock AN Biomedicines; 2021 Jan; 9(2):. PubMed ID: 33572801 [TBL] [Abstract][Full Text] [Related]
30. Recent progress in drug development for fibrodysplasia ossificans progressiva. Meng X; Wang H; Hao J Mol Cell Biochem; 2022 Oct; 477(10):2327-2334. PubMed ID: 35536530 [TBL] [Abstract][Full Text] [Related]
31. [Genetic basis for skeletal disease. Establishment of novel treatments for fibrodysplasia ossificans progressiva (FOP)]. Katagiri T Clin Calcium; 2010 Aug; 20(8):1204-11. PubMed ID: 20675931 [TBL] [Abstract][Full Text] [Related]
32. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055 [TBL] [Abstract][Full Text] [Related]
33. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva. Kaplan FS; Seemann P; Haupt J; Xu M; Lounev VY; Mullins M; Shore EM Methods Enzymol; 2010; 484():357-73. PubMed ID: 21036241 [TBL] [Abstract][Full Text] [Related]
34. Multi-system involvement in a severe variant of fibrodysplasia ossificans progressiva (ACVR1 c.772G>A; R258G): A report of two patients. Kaplan FS; Kobori JA; Orellana C; Calvo I; Rosello M; Martinez F; Lopez B; Xu M; Pignolo RJ; Shore EM; Groppe JC Am J Med Genet A; 2015 Oct; 167A(10):2265-71. PubMed ID: 26097044 [TBL] [Abstract][Full Text] [Related]
35. Drosophila models of FOP provide mechanistic insight. Le V; Anderson E; Akiyama T; Wharton KA Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351 [TBL] [Abstract][Full Text] [Related]
36. Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors. Sanchez-Duffhues G; Williams E; Goumans MJ; Heldin CH; Ten Dijke P Bone; 2020 Sep; 138():115472. PubMed ID: 32522605 [TBL] [Abstract][Full Text] [Related]
37. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707 [TBL] [Abstract][Full Text] [Related]
38. Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva. Takahashi M; Katagiri T; Furuya H; Hohjoh H Gene Ther; 2012 Jul; 19(7):781-5. PubMed ID: 22130450 [TBL] [Abstract][Full Text] [Related]
39. Fibrodysplasia ossificans progressiva (FOP): A disorder of osteochondrogenesis. Kaplan FS; Al Mukaddam M; Stanley A; Towler OW; Shore EM Bone; 2020 Nov; 140():115539. PubMed ID: 32730934 [TBL] [Abstract][Full Text] [Related]